Each spray delivers: 600 μg olopatadine (as olopatadine hydrochloride) and 25 μg mometasone furoate (as Mometasone furoate monohydrate).
Ryaltris nasal spray is indicated for the symptomatic treatment of seasonal or perennial allergic rhinitis and associated ocular symptoms in adults and children of 6 years and older.
Patients with known hypersensitivity to olopatadine hydrochloride, mometasone furoate, or any ingredients of RYALTRIS. It is contraindicated in pregnancy and lactating mothers.
Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma. Risk of immunosuppression, use with caution in any fungal, bacterial, and viral infections. Hypercortisolism and adrenal suppression with higher than recommended dosages or at the regular dosage in susceptible individuals; use in caution in paediatric patient and regularly monitor the growth. Somnolence - Avoid engaging in hazardous occupations requiring complete mental alertness and motor coordination. Avoid concurrent use with alcohol or CNS depressant drugs. Drug interactions: Any medicine interactions from the combination of olopatadine and mometasone furoate are expected to reflect those of the components taken individually.
Nasal ulcerations, nasal septal perforations, epistaxis, impaired wound healing, and Candida albicans infection.
Allergic rhinitis (AR), an inflammatory disease of the upper airways, is the most common allergic disease affecting every patient’s quality of life, whether they are young or old. Therefore, Glenmark presents – Ryaltris Nasal Spray, a combination treatment for all age groups because we believe that every patient matters.
Adults and Adolescents (12 years of age & older) :
The recommended dose of Ryaltris is 2 sprays in each nostril twice daily (morning and evening).
Children (6 to 11 years of Age) :
The recommended dose of Ryaltris is 1 spray in each nostril twice daily (morning and evening).